Immune Response Visualized In Vivo by [18F]-FDG PET/CT after COVID-19 Vaccine.

COVID-19 vaccine [18F]-FDG PET/CT immune response lymph nodes spleen

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
09 Apr 2021
Historique:
received: 26 03 2021
revised: 06 04 2021
accepted: 08 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

Worldwide deployment of COVID-19 vaccines is in progress. Recent immune activation following vaccination can sometimes be seen in fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT). As previously evidenced, FDG-avid axillary lymph node(s) are common in patients receiving vaccines against SARS-CoV-2, influenza virus, or human papillomavirus, and reflect a regional immune response. In addition, these findings may also be accompanied by an increased spleen glucose metabolism after the COVID-19 vaccine, which captures a systemic immune response. Hence, we provide here a clinical example demonstrating that immune response could be associated with increased glucose metabolism in lymphoid organs such as lymph nodes and the spleen, which are critical modulators of T cell immunity. We believe that it is of paramount importance that nuclear physicians should be able to recognize clinical and imaging features of such immune responses upon vaccination for COVID-19 and beyond.

Identifiants

pubmed: 33918702
pii: diagnostics11040676
doi: 10.3390/diagnostics11040676
pmc: PMC8069156
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Eur J Nucl Med Mol Imaging. 2021 Mar 6;:
pubmed: 33675368
JACC Cardiovasc Imaging. 2015 Feb;8(2):121-30
pubmed: 25577441
Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1813-21
pubmed: 19499219
Lancet. 2021 Mar 20;397(10279):e9
pubmed: 33705696
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1467-1477
pubmed: 33106925
J Nucl Med. 1999 Sep;40(9):1456-62
pubmed: 10492365
Nat Med. 2021 Mar;27(3):515-525
pubmed: 33479501
Eur J Nucl Med Mol Imaging. 2021 Feb 26;:
pubmed: 33638003

Auteurs

Romain-David Seban (RD)

Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.
Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401 Orsay, France.

Laurence Champion (L)

Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.
Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401 Orsay, France.

Nicolas Deleval (N)

Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.

Capucine Richard (C)

Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.

Claire Provost (C)

Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401 Orsay, France.
Department of Pharmacology, Institut Curie, 92210 Saint-Cloud, France.

Classifications MeSH